Key Insights

Highlights

Treatment Research

1 treatments under study, led by 68gadotafapi 177ludotafapi

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT04849247Phase 1Unknown

68Ga-DOTA-FAPI and 177Lu-DOTA-FAPI Theranostic Pair in Patients With Various Types of Cancer (Locally Advanced or Metastatic Cancer)

Showing all 1 trials

Research Network

Common Treatments

  • 68gadotafapi 177ludotafapi1

Active Sponsors

  • The First Affiliated Hospital of Xiamen University1

Top Investigators

Related Conditions

  • Theranostic1
  • 177ludotafapi1

Activity Timeline